GHRP-2 vs PT-141 (Bremelanotide)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHRP-2PT-141 (Bremelanotide)
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
TimingOn empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
Cycle Duration8-16 week cycles.As-needed basis. Not intended for daily use.
Evidence Levelmoderate_humanstrong_human
A

GHRP-2

Peptides

Mechanism

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.

Cycle Duration

8-16 week cycles.

Side Effects

  • Water retention
  • Moderate hunger increase (less than GHRP-6)
  • Cortisol elevation
  • Prolactin elevation
  • Tingling
  • Vivid dreams

Contraindications

  • Active cancer
  • Cushing's syndrome
  • Hyperprolactinemia
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)SermorelinBPC-157

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Standard Dosing

Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Timing

45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Cycle Duration

As-needed basis. Not intended for daily use.

Side Effects

  • Nausea (most common, dose-dependent)
  • Flushing
  • Headache
  • Nasal congestion (intranasal route)
  • Transient blood pressure increase
  • Skin darkening with repeated use

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Use of other melanocortin agonists concurrently

Best Stacking Partners

Kisspeptin-10Melanotan II

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →